Abstracts
Showing 737 abstracts.
Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093
Conference
XIX International AIDS Conference
Study
P1093
Size and Decay of the Resting CD4+ T Cell Latent HIV Reservoir in Early-Treated Infants.
Conference
XIX International AIDS Conference
Study
P1030
IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48
Conference
XIX International AIDS Conference
Study
P1066
Tenofovir Disoproxil Fumarate (TDF) Pharmacokinetics (PK) with Daily Dosing in the First Week of Life (HPTN 057)
Conference
XIX International AIDS Conference
Association of Tenofovir Disoproxil Fumarate with Neonatal Growth
Conference
XIX International AIDS Conference
Study
P1025
Comparison of HIV-Genotyping Results Obtained from Next-generation Sequencing of Plasma and Dried Blood Spot Samples
Conference
XIX International AIDS Conference
Study
P1060
Effect of Pregnancy on Pharmacokinetics of Boosted Indinavir
Conference
13th International Workshop on Clinical Pharmacology of HIV Therapy
Study
P1026S
Raltegravir (RAL Pharmacokinetics (PK) and Safety in Neonates (IMPAACT P1097)
Conference
13th International Workshop on Clinical Pharmacology of HIV Therapy
Study
P1097
Impact of body weight on the risk of low lopinavir/r concentrations during the third trimester of pregnancy in HIV-infected Thai and US Women
Conference
13th International Workshop on Clinical Pharmacology of HIV Therapy
Interim Results from IMPAACT P1066: Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age
Conference
19th Conference on Retroviruses and Opportunistic Infections
Study
P1066